{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:28:25Z","timestamp":1775500105852,"version":"3.50.1"},"reference-count":29,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14586","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:59:23Z","timestamp":1721735963000},"source":"Crossref","is-referenced-by-count":3,"title":["Misdiagnosis of severe and atypical oxaliplatin\u2011related hypersensitivity reaction following chemotherapy combined with PD\u20111 inhibitor: A case report and literature review"],"prefix":"10.3892","volume":"28","author":[{"given":"Maoben","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Oncology, Binhaiwan Central Hospital of Dongguan, Dongguan, Guangdong 523000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guihua","family":"Xu","sequence":"additional","affiliation":[{"name":"Dongguan Key Laboratory of Precision Medicine, Binhaiwan Central Hospital of Dongguan, Dongguan, Guangdong 523000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhen","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binhaiwan Central Hospital of Dongguan, Dongguan, Guangdong 523000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaozhong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, Binhaiwan Central Hospital of Dongguan, Dongguan, Guangdong 523000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"key20240906090733_b1-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: Implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240906090733_b2-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240906090733_b3-ol-28-4-14586","first-page":"1671167616801683","article-title":"Hypersensitivity reactions to oxaliplatin: Incidence and management","volume":"18","author":"Gowda","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"key20240906090733_b4-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"S4000","DOI":"10.1200\/JCO.2023.41.16_suppl.4000","article-title":"ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G\/GEJ) cancer","volume":"41","author":"Terashima","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20240906090733_b5-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1023\/A:1011161126611","article-title":"Reaction after oxaliplatin-prevention with corticosteroids?","volume":"12","author":"Stahl","year":"2001","journal-title":"Ann Oncol"},{"key":"key20240906090733_b6-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1023\/A:1008366223918","article-title":"Idiosyncratic reaction after oxaliplatin infusion","volume":"12","author":"Santini","year":"2001","journal-title":"Ann Oncol"},{"key":"key20240906090733_b7-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity reactions related to oxaliplatin (OHP)","volume":"89","author":"Brandi","year":"2003","journal-title":"Br J Cancer"},{"key":"key20240906090733_b8-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"key20240906090733_b9-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdj042","article-title":"Hypersensitivity reactions to oxaliplatin: Experience in a single institute","volume":"17","author":"Siu","year":"2006","journal-title":"Ann Oncol"},{"key":"key20240906090733_b10-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0929-6646(10)60064-2","article-title":"Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions","volume":"109","author":"Shao","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"key20240906090733_b11-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-6511-15-1","article-title":"Hypersensitivity to oxaliplatin: Clinical features and risk factors","volume":"15","author":"Parel","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"key20240906090733_b12-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.clinthera.2015.03.012","article-title":"Hypersensitivity reactions to oxaliplatin: Identifying the risk factors and judging the efficacy of a desensitization protocol","volume":"37","author":"Okayama","year":"2015","journal-title":"Clin Ther"},{"key":"key20240906090733_b13-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3727\/096504017X15139039328978","article-title":"Clinical analysis of hypersensitivity reactions to oxaliplatin among colorectal cancer patients","volume":"26","author":"Shen","year":"2018","journal-title":"Oncol Res"},{"key":"key20240906090733_b14-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.jaip.2017.12.026","article-title":"Incidence and risk of oxaliplatin-induced hypersensitivity in patients with asymptomatic prior exposure: A prospective observational study","volume":"6","author":"Sohn","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key20240906090733_b15-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.3390\/biomedicines10123275","article-title":"Oxaliplatin-related hypersensitivity reactions: A single institution series and literature review","volume":"10","author":"Barbin","year":"2022","journal-title":"Biomedicines"},{"key":"key20240906090733_b16-ol-28-4-14586","first-page":"2640","article-title":"Oxaliplatin-induced hypersensitivity reactions: Risk factors and management","volume":"27","author":"Selcuk","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20240906090733_b17-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20240906090733_b18-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"key20240906090733_b19-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"key20240906090733_b20-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"e26642","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"key20240906090733_b21-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000178163","article-title":"Clinical features of hypersensitivity reactions to oxaliplatin: A 10-year experience","volume":"76","author":"Polyzos","year":"2009","journal-title":"Oncology"},{"key":"key20240906090733_b22-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"key20240906090733_b23-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20240906090733_b24-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cmi.2018.12.028","article-title":"How to: Implement procalcitonin testing in my practice","volume":"25","author":"Neeser","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"key20240906090733_b25-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"key":"key20240906090733_b26-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"key20240906090733_b27-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240906090733_b28-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"906824","DOI":"10.3389\/fonc.2022.906824","article-title":"Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"key20240906090733_b29-ol-28-4-14586","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:07:39Z","timestamp":1725602859000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14586","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"article-number":"452"}}